日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Survival benefit of neoadjuvant chemotherapy in HR+/HER2- early breast cancer stratified by luminal B status and clinical risk: a real-world cohort study in a Chinese population

新辅助化疗对HR+/HER2-早期乳腺癌患者的生存获益：基于Luminal B分型和临床风险分层的中国人群真实世界队列研究

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2026.1804093
Wang, Wei; Liang, Xueyan; Yang, Yuchao; Zhang, Wenhai; Huang, Denghua; Li, Jiajun; Liu, Yukun; Ren, Hui
肿瘤
乳腺癌
肿瘤免疫
HER2
发表日期：2026
文献求助 收藏

Metabolites mediate the effects of healthy lifestyles on the risks of common age-related diseases

代谢产物介导健康生活方式对常见年龄相关疾病风险的影响

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2025.1654172
Li, Yan; Li, Huijuan; Chen, Xiaoyu; Liang, Xueyan
代谢
发表日期：2025
文献求助 收藏

Estimated glucose disposal rate and frailty in middle and older aged adults from three prospective cohorts

来自三个前瞻性队列的中老年人葡萄糖处置率和虚弱程度的估计

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-025-28740-w
Li, Yan; Ye, Xi; Chen, Xiaoyu; Liang, Xueyan
发表日期：2025
文献求助 收藏

Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow

利用创新的KMSubtraction工作流程，重建晚期/转移性三阴性乳腺癌中PD-L1低表达的未报告亚组生存数据。

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2023-007931
Li, Yan; Liang, Xueyan; Li, Huijuan; Chen, Xiaoyu
肿瘤
肿瘤免疫
多发性硬化症
乳腺癌
PD-L1
发表日期：2024
文献求助 收藏

Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system

非小细胞肺癌免疫检查点抑制剂相关不良事件：临床试验和FDA药物警戒系统的安全性分析

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2024.1396752
Liang, Xueyan; Xiao, Hewei; Li, Huijuan; Chen, Xiaoyu; Li, Yan
细胞生物学
肿瘤
免疫/内分泌
肿瘤免疫
肺癌
发表日期：2024
文献求助 收藏

Association between various insulin resistance indices and cardiovascular disease in middle-aged and elderly individuals: evidence from two prospectives nationwide cohort surveys

中老年人群中各种胰岛素抵抗指标与心血管疾病的关联：来自两项前瞻性全国队列调查的证据

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2024.1483468
Li, Yan; Li, Huijuan; Chen, Xiaoyu; Liang, Xueyan
代谢
心血管疾病
心血管
免疫/内分泌
发表日期：2024
文献求助 收藏

Rapid and sensitive detection of methicillin-resistant Staphylococcus aureus through the RPA-PfAgo system

利用RPA-PfAgo系统快速灵敏地检测耐甲氧西林金黄色葡萄球菌

期刊:Frontiers in Microbiology
影响因子:4.5
doi:10.3389/fmicb.2024.1422574
Chen, Weizhong; Zhang, Jiexiu; Wei, Huagui; Su, Jie; Lin, Jie; Liang, Xueyan; Chen, Jiangtao; Zhou, Rong; Li, Lin; Lu, Zefang; Sun, Guangyu
发表日期：2024
文献求助 收藏

Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis

纳武利尤单抗联合伊匹木单抗与 EXTREME 方案治疗复发/转移性头颈部鳞状细胞癌的成本效益分析

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-57277-7
Ye, Dongmei; Liang, Xueyan; Chen, Xiaoyu; Li, Yan
肿瘤免疫
细胞生物学
肿瘤
发表日期：2024
文献求助 收藏

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis

一线serplulimab联合化疗与单纯化疗治疗PD-L1阳性食管鳞状细胞癌的成本效益分析

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-65474-7
Liang, Xueyan; Meng, Mingyu; Qin, Shiran; Chen, Xiaoyu; Li, Yan
PD-L1
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma

替雷利珠单抗联合化疗治疗中国晚期或转移性食管鳞状细胞癌患者的成本效益分析

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/s41598-024-68399-3
Zhang, Li; Su, Henghai; Liang, Xueyan; Chen, Xiaoyu; Li, Yan
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏